

Evidence-based Synthesis Program (ESP)

Predictors and Consequences of Severe Hypoglycemia in Adults with Diabetes

A Systematic Review of the Evidence

Hanna E. Bloomfield, MD, MPH
Staff Physician
Minneapolis VA Health Care System



June 25, 2012

Evidence-based Synthesis Program (ESP)

Acknowledgements

Co-Authors/Collaborators

- Nancy Greer, PhD
- David Newman, MD
- Timothy Wilt, MD,MPH

Expert Panel/Reviewers

- David C. Aron, MD, MS
- Stephen Davis, MBBS, FACP
- William Duckworth, MD
- Devan Kansagara, MD
- Debbie Khachikian, Pharm D
- Leonard Pogach, MD, MBA, FACP
- Matthew Riddle, MD

Evidence-based Synthesis Program (ESP)



Disclosure

This report is based on research conducted by the Evidence-based Synthesis Program (ESP) Center located at the Minneapolis VA HealthCare System, Minneapolis Minnesota funded by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Quality Enhancement Research Initiative. The findings and conclusions in this document are those of the author(s) who are responsible for its contents; the findings and conclusions do not necessarily represent the views of the Department of Veterans Affairs or the United States government. Therefore, no statement in this article should be construed as an official position of the Department of Veterans Affairs. No investigators have any affiliations or financial involvement (e.g., employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties) that conflict with material presented in the report.

Evidence-based Synthesis Program (ESP)

VA Evidence-based Synthesis (ESP) Program Overview

- Sponsored by VA Office of Research & Development, Quality Enhancement Research Initiative (QUERI).
- Established to provide timely and accurate syntheses/reviews of healthcare topics identified by VA clinicians, managers and policy-makers, as they work to improve the health and healthcare of Veterans.
- Builds on staff and expertise already in place at the Evidence-based Practice Centers (EPC) designated by AHRQ. Four of these EPCs are also ESP Centers:
 - Durham VA Medical Center; VA Greater Los Angeles Health Care System; Portland VA Medical Center; and Minneapolis VA Medical Center.

Evidence-based Synthesis Program (ESP)

- Provides evidence syntheses on important clinical practice topics relevant to Veterans, and these reports help:
 - develop clinical policies informed by evidence,
 - the implementation of effective services to improve patient outcomes and to support VA clinical practice guidelines and performance measures, and
 - guide the direction for future research to address gaps in clinical knowledge.
- Broad topic nomination process – e.g. VACO, VISNs, field – facilitated by ESP Coordinating Center (Portland) through online process:

<http://www.hsrd.research.va.gov/publications/esp/TopicNomination.cfm>

Evidence-based Synthesis Program (ESP)

- Steering Committee representing research and operations (PCS, OQP, ONS, and VISN) provides oversight and guides program direction.
- Technical Expert Panel (TEP)
 - Recruited for each topic to provide content expertise.
 - Guides topic development; refines the key questions.
 - Reviews data/draft report.
- External Peer Reviewers & Policy Partners
 - Reviews and comments on draft report
- Final reports posted on VA HSR&D website and disseminated widely through the VA.

<http://www.hsrd.research.va.gov/publications/esp/reports.cfm>

Evidence-based Synthesis Program (ESP)



Predictors and Consequences of Severe Hypoglycemia in Adults with Diabetes (June 25 2012)

Full-length report available on ESP website:

<http://www.hsrd.research.va.gov/publications/esp/reports.cfm>

Background

- Prevalence of Type 2 Diabetes increasing
 - Estimated at 25% in VA
- Associated with increased risk of CVD
- National guidelines have emphasized very tight glucose control
 - Prevent microvascular complications
- Tight control associated with hypoglycemia


Key Questions

- What is the incidence of severe hypoglycemia in adults with Type 2 Diabetes on one or more hypoglycemic agents?
- What are the risk factors for severe hypoglycemia in this population?
- What are the consequences of severe hypoglycemia?

Methods

- Medline search for trials, observational studies and systematic reviews (1950 to November 2011) of adults with type 2 diabetes on diabetes medication
- Severe hypoglycemia defined as an episode with typical symptoms resolving after treatment (IV glucose, IM glucagon or PO carbohydrate) administered by another person
- For KQ1 and 2, studies with < 500 subjects or < 6 months duration were excluded

Literature Search



KQ1: Incidence

- 60 studies (72 articles)
 - most were RCTS (46) & funded by drug companies (47)
 - 5 intensive vs. standard control
- Only 12/46 RCTS were rated as good quality
- Severe hypoglycemia seen infrequently in studies of
 - Metformin, Glinides, Detemir
 - TZDs, GLP-1 Analogs
 - DPP-4 inhibitors

KQ1: Incidence

- Highest rates for...
- Insulins
 - NPH monotherapy 9.3% over 3.5 yrs* (95% CI 7.3 to 11.8, N=763, 2 studies)
 - Glargine
 - > 2 years: 4.1% (95% CI 1.9 to 8.4%, N=1223, 3 studies)
 - < 1 yr: 1.6% (95% CI 1.6%, 95% 0.8 to 3.2%, N=13,088, 5 studies)
 - Lispro 3.6% over 1.3 yrs* (95% CI 2.3 to 5.4, N=1198, 2 studies)
 - Glulisine + NPH 1.0% over 0.5 years* (95% CI 0.5 to 2.1%, N=883, 2 studies)
- Sulfonylureas 1.2% over 2.3 yrs* (95% CI 0.9 to 1.4, N=9081, 13 studies)

* *weighted mean average duration*

KQ1: Intensive Control


Study	Standard	Intensive	Average Follow-up (Years)	Definition	Glycemic Targets (standard /intense)
ACCORD ³	261/5123 (5.1%)	830/5128 (16.2%)	3.5	HA	A1c 7.0 – 7.9 A1c < 6.0
ADVANCE ⁴	81/5569 (1.5%)	150/5571 (2.7%)	5.0	HA	Local standards A1c ≤ 6.5
VA-DT ⁵	28/899 (3.1%)	76/892 (8.5%)	5.6	**	A1c < 9 A1c < 6
VA-CSDM ³⁰	2/78 (2.6%)	5/75 (6.6%)	2.3	HA	A1c < 13 A1c 4.0 – 6.1
UKPDS ^{#21, 29}	8/1138 (0.7%)	33/3071 (1.1%)	10.0	HA	FPG 6.1 – 15.0 mmol/l FPG < 6.0 mmol/l
POOLED	3.1%	7.6%	5.2 yrs		RR 2.4 (95% CI 1.8 to 3.1, N=27,644)

**** life threatening or resulted in death, hospitalization, disability or incapacity, # data for the 2 UKPDS studies are combined as per Hemmingsen 2011, HA—episode of hypoglycemia requiring assistance of another person**

KQ1: Population-Based

- **In order to gain a more population-based perspective on hypoglycemia incidence**
- **We re-reviewed all the abstracts to find articles with data from more representative groups...**
 - Population or clinic based (no drug RCTs)
- **...using more liberal inclusion criteria**
 - <500 people, duration < 6 months
 - Definition of severe hypoglycemia not as rigorous
 - Lack of true incidence data (cross sectional surveys)

Literature Search



KQ1: Incidence

- 13 survey studies (patient recall)
 - 5 six month studies in pts on oral agents only
 - 1-13% incidence hypoglycemia requiring any assistance (HA)
 - 1-4% incidence hypoglycemia requiring medical assistance (HMA)
 - 3 one year studies in pts on insulin only
 - 12-17% HA
 - 2% HMA
- 1 prospective study
 - 1 month community based in Scotland
 - 173 adults
 - 3% incidence of HA

KQ1: VA Specific Data

- Four of our included studies were of VA patients
- 2 additional VA studies did not meet our inclusion criteria or were published later
- These studies suggest that VA patients may experience higher incidence rates than the general population

KQ1: Limitations

- **Data mostly from drug company sponsored trials**
 - highly selected pts
 - ascertainment bias
- **Population based data**
 - patient recall
 - lack of standard definitions

KQ1: Summary

- Incidence of severe hypoglycemia: 0-3%/yr
- Highest for
 - Insulins
 - Sulfonylureas
 - Regimens targeting tight control
- Prospective population based studies needed
 - VA and non-VA

KQ2

- What are the risk factors for severe hypoglycemia in adults with Type 2 diabetes on one or more hypoglycemic agents?

KQ2: Risk Factors for Hypoglycemia

- 28 studies (31 articles)
- Only the 12 studies that used multivariate analysis are reported
 - 2 RCTs
 - 2 cohort
 - 4 cross-sectional
 - 4 case control

KQ2: Risk Factors for Hypoglycemia

- Transient causes (e.g. missed meal, excess exercise, alcohol use, acute infection) were not included
- All studies met pre-specified definition of severe hypoglycemia
- Data were unsuitable for pooling
 - lengths of f/u
 - risk factors
 - populations

KQ2: Independent Risk Factors Consistently Associated with Risk of Hypoglycemia

- Demographics
 - lower education level
 - African American race
- Medical History
 - past hypoglycemia
 - renal insufficiency
 - non-renal microvascular complications
 - dementia
 - longer diabetes duration
- Treatment
 - intensive diabetes control

KQ2: Independent Risk Factors NOT Consistently Associated with Risk of Hypoglycemia

- **Gender, Age and BMI**
 - In the two largest studies, higher age and lower BMI were significantly associated with higher risk

KQ2: Inadequately Studied Risk Factors

- h/o hypoglycemia unawareness
- genetic markers
- marital status
- smoking
- alcohol consumption
- polypharmacy
- recent discharge from the hospital
- congestive heart failure
- use of ACE inhibitors


KQ2: Limitations and Summary

- Publication Bias
 - Negative studies unlikely to be reported
- Risk Factors
 - lower education level
 - African American race
 - past hypoglycemia
 - renal insufficiency
 - non-renal microvascular complications
 - dementia
 - longer diabetes duration
 - intensive diabetes control
 - ?higher age
 - ?lower BMI

KQ3

- What are the consequences of severe hypoglycemia?

KQ3: Ideal Study Design



Features of an Ideal Study

- Population based
- Prospective
- Controlled
 - People with diabetes on medications who did NOT have hypoglycemia
- *Most studies were far from this ideal*


KQ3: Consequences of Hypoglycemia

- 59 articles on 53 studies
- Consequences
 - Complications at Presentation
 - Long-Term Outcomes
 - All-cause mortality
 - Cognitive Impairment
 - Quality of Life

Complications at Presentation

- Retrospective cohort study of 19,932 Tennessee medicaid enrollees, age ≥ 65 , on oral hypoglycemics or insulin
 - ✓ Population-based
 - +/- Prospective
 - ✗ Control Group

Study Design



Follow-up \circ Schorr et al Arch Intern Med 1997;157:1681

Complications at Presentation

- 586 persons with a first episode of serious hypoglycemia occurring outside the hospital that resulted in an ER visit, hospitalization or death
- 5% of these episodes were associated with ‘catastrophic complications’ including
 - Stroke (1.2%) or TIA (0.6%)
 - MI (0.5%)
 - Injury (1.7%)
 - Death (0.3%)

Long Term Outcomes: Mortality

ACCORD and ADVANCE

+/- Population-based

- RCTs, but liberal entrance criteria

✓ Prospective

- With long follow-up

✓ Control Group

- With no episodes of hypoglycemia

Mortality

- Severe hypoglycemia was associated with an increased risk of death in both ACCORD and ADVANCE

Mortality

in people without a h/o severe hypoglycemia

Study	Mortality			
	Intensive		Standard	
Hypoglycemia	Yes	No	Yes	No
ACCORD (annual)	2.8%	1.2%	3.7%	1.0%
ADVANCE (annual)	3.6%	1.8%	5.1%	1.9%
UKPDS (10 yr)	12.5%	NR	0%	NR

Mortality

in people with a h/o severe hypoglycemia

Study	Mortality			
	Intensive		Standard	
Hypoglycemia	Yes	No	Yes	No
ACCORD (annual)	2.8%	1.2%	3.7%	1.0%
ADVANCE (annual)	3.6%	1.8%	5.1%	1.9%
UKPDS (10 yr)	12.5%	NR	0%	NR

Long term Outcomes: Cognitive Impairment

- 2 high quality cohort studies (Whitmer 2009, Bruce 2009)
 - Population-based (both)
 - Prospective (Bruce)
 - Control Group (both)
- However *Bruce 2009* was grossly underpowered
 - N=205 followed for < 2 years

Cognitive Impairment

Whitmer

- 16,667 pts with diabetes from a healthcare plan in California
- 3.8 years of follow-up for incident dementia (retrospective cohort)
- 1465 (8.8%) with one or more episodes of hypoglycemia identified retrospectively
- **Increased risk of dementia in those with 1 or more episodes (HR 1.68, 95% CI 1.47 to 1.93)**

Long term Outcomes: Quality of Life

- 8 cross-sectional studies
 - 5 had 1/3 quality indicators*
 - 2 had 2/3 quality indicators
 - 1 had 0/3

**Population based, prospective, control group*

Quality of Life

Study	Quality Indicators	HRQoL	Worry/ Fear	Other
Marrett, USA, 2009	2/3	↓	↑	
Labad, Scotland, 2010	2/3	-	-	Increased anxiety
Petterson, Sweden, 2011	1/3	↓	↑	
Hermanns, Germany, 2005	1/3	-	-	Increased anxiety & depression
Alvarez, Europe, 2010	1/3	↓	-	
Vexiau, France, 2008	1/3	↓	↑	
Davis, UK, 2005	1/3	-	-	Decreased productivity

In diabetics reporting severe hypoglycemia compared to those reporting no severe hypoglycemia

All results are significant at $p < 0.05$

Accidents / Trauma

- No high quality studies
- ACCORD
 - No difference in # of MVAs in which pt was a driver between intense and standard control

KQ3 Summary

- There is evidence that severe hypoglycemia
 - Decreases quality of life
 - Is associated with increased mortality
 - May lead to cognitive impairment
 - Increases hospital and ER utilization (data not shown)
- Limitations
 - Few high quality studies (population based, prospective, control group)

Conclusions


In patients with diabetes on medications...

- Incidence of severe hypoglycemia is difficult to quantify but is not negligible
- Several co-morbidities, demographic and treatment related factors increase the risk
- Severe hypoglycemia has a negative effect on QoL and can lead to serious outcomes including death
- Intensity of glucose control is the risk factor most amenable to intervention

National Recommendations

Goal A1C: “< 7% in most patients”

ADA Standards of Medical Care (2011)




Patient centered approach

Less stringent goal (7.5 to 8.0) appropriate for some

ADA and EASD (2012)

Patient-centered Approach

ADA and EASD (2012)





VA-DoD Guidelines 2010

- Individualized goal based on...
 - Co-morbidities
 - Life expectancy
 - Risk of hypoglycemia
 - Presence of pre-existing microvascular complications
 - Patient's preferences



VA-DoD Guidelines 2010



Goal A1C

Microvascular complications

Life Expectancy	Absent or Mild	Moderate	Advanced
> 10 years	<7%	<8%	8-9%
5-10 years	< 8%	<8%	8-9%
< 5 years	8-9%	8-9%	8-9%



Evidence-based Synthesis Program (ESP)



Questions?

If you have further questions,
feel free to contact:

Hanna E. Bloomfield, MD, MPH
Staff Physician, Minneapolis VA
612-725-2000
Hanna.Bloomfield@va.gov

The full report and cyberseminar presentation is available on the ESP website:

<http://www.hsrd.research.va.gov/publications/esp/>

Key Summary Points Regarding Potential Risk of Hypoglycemia in Veterans

Leonard Pogach MD, MBA, FACP

National Program Director Endocrinology and
Diabetes

Bernie Good MD, MPH

Chair Medication Advisory Panel

ACCORD

- Increased mortality (2.8%) in intensively managed patients who had one or more severe hypoglycemic episodes compared to those with no episodes (1.2%) (adjusted HR 1.41; 95% CI, 1.03-1.93).
- Trend was also seen in the standard control group: 3.7% vs. 1.0%, respectively (adjusted HR 2.3; 95% CI, 1.46-3.6).


ADVANCE

- Severe hypoglycemia was associated with a significant increase in the adjusted risks of major macrovascular events (hazard ratio, 2.88; 95% confidence interval [CI], 2.01 to 4.12), major microvascular events (hazard ratio, 1.81; 95% CI, 1.19 to 2.74), death from a cardiovascular cause (hazard ratio, 2.68; 95% CI, 1.72 to 4.19), and death from any cause (hazard ratio, 2.69; 95% CI, 1.97 to 3.67) ($P < 0.001$ for all comparisons).
- Similar associations were apparent for a range of nonvascular outcomes, including respiratory, digestive, and skin conditions ($P < 0.01$ for all comparisons).

Predictors of CV Death, VADT

Davis, S. ADA 2009

Hazard Ratio
(HR Lower CL, HR Upper CL) P Value



Risk of Morbidity and Mortality from Severe Hypoglycemia from ACCORD, ADVANCE , VADT

- Association with adverse outcomes greatest with control arms (A1cs achieved 7.5, 7.0, 8.4.% respectively).
- Risk greater in subjects with chronic co-morbid conditions
- Unlikely that post-hoc observational data sets will disentangle relationship of hypoglycemia to outcomes

Risk Factors for Serious Hypoglycemia Among Veterans Under-Represented in Trials

- 2004 Risk Factors <65 years (Pogach et al. Diabetes Care 2010)
 - Complex Glycemic Regimens 30%
 - Decreased Life Expectancy, 5.4%
 - Advanced Complications 6.3%
 - Serious Medical Conditions 9.0%
 - Serious Neurological Conditions 4.2%
 - Serious Mental Health Conditions 21.5%
 - Poverty 28%; disability >50% 31.3%

Conclusions:

- The Veteran population is at high risk for serious hypoglycemia due to age, risk factors (medical, socio-economic)
- Incidence/Prevalence of serious hypoglycemia not likely to be known with greater certainty without weighted population health surveys.
- Clinicians need to balance benefits of good glycemic control with potential harms associated with hypoglycemia, especially in vulnerable veterans
- PBM will address issue of anti-glycemic safety among those high risk Veterans in near future.